利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.017 秒)

    Hydrogenation of nitrile group-containing unsaturated polymers
    1.
    发明授权
    Hydrogenation of nitrile group-containing unsaturated polymers 失效
    含腈基不饱和聚合物的氢化

    公开(公告)号：US4631315A

    公开(公告)日：1986-12-23

    申请号：US771646

    申请日：1985-09-03

    申请人： Hartmuth Buding ,  Paul Fiedler ,  Heinrich Konigshofen ,  Joachim Thormer

    发明人： Hartmuth Buding ,  Paul Fiedler ,  Heinrich Konigshofen ,  Joachim Thormer

    IPC分类号： C08F8/00 ,  B01J31/00 ,  B01J31/16 ,  C08C19/02 ,  C08F8/04 ,  C08F236/00 ,  C08F236/12

    CPC分类号： C08C19/02

    摘要： Nitrile group-containing polymers are hydrogenated in a homogeneous phase with preservation of the nitrile groups in a low molecular weight ketone as a solvent and with a compound corresponding to formulaRuX[(L.sub.1)(L.sub.2).sub.n ]as a catalyst, whereinX represents hydrogen, halogenL.sub.1 represents hydrogen, halogen, optionally substituted cyclopentadienyl,L.sub.2 represents a phosphane, bisphosphane or arsane andn is 1, 2 or 3 and[(L.sub.1)(L.sub.2).sub.n ] represents a cyclopentadienyl bisphosphane.

    摘要翻译： 含腈基的聚合物以均相形式被氢化，在作为溶剂的低分子量酮中保留腈基，并使用对应于式RuX [（L1）（L2）n]的化合物作为催化剂，其中X表示 氢，卤素L 1代表氢，卤素，任选取代的环戊二烯基，L 2代表一种膦，二膦或二异氰酸酯，n是1,2或3，[（L1）（L2）n]代表环戊二烯基双膦。

    Process for the selective hydrogenation of unsaturated compounds
    3.
    再颁专利
    Process for the selective hydrogenation of unsaturated compounds 失效
    不饱和化合物的选择性氢化方法

    公开(公告)号：USRE34548E

    公开(公告)日：1994-02-15

    申请号：US922011

    申请日：1992-07-29

    申请人： Paul Fiedler ,  Hartmuth Buding ,  Rudolf Braden

    发明人： Paul Fiedler ,  Hartmuth Buding ,  Rudolf Braden

    IPC分类号： C08C19/02 ,  C08F8/04

    CPC分类号： C08C19/02 ,  C08F8/04

    摘要： The selective hydrogenation of unsaturated compounds which carry reducible groups containing nitrogen succeeds in a homogeneous phase with the preservation of the reducible groups containing nitrogen, characterized in that a compound of the formulaRuH.sub.2n L.sub.5-nis used as a catalyst, in whichL signifies a phosphane or arsane andn signifies 1 or 2.

    摘要翻译： 含有氮的还原基团的不饱和化合物的选择性氢化在保持含氮可还原基团的同质相中成功，其特征在于使用式RuH 2 nL 5-n的化合物作为催化剂，其中L表示磷烷 或者arsane和n表示1或2。

    Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood
    8.
    发明申请
    Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood 失效

    公开(公告)号：US20050239058A1

    公开(公告)日：2005-10-27

    申请号：US11155856

    申请日：2005-06-20

    申请人： David Rimm ,  Paul Fiedler ,  Robert Levine ,  Stephen Wardlaw

    发明人： David Rimm ,  Paul Fiedler ,  Robert Levine ,  Stephen Wardlaw

    IPC分类号： C07K16/10 ,  C12Q1/70 ,  G01N15/04 ,  G01N33/569 ,  G01N33/574 ,  G01N33/68

    CPC分类号： G01N33/56972 ,  C07K16/109 ,  G01N15/042 ,  G01N33/57484 ,  G01N33/6878 ,  G01N2015/045 ,  Y10S436/81

    摘要： A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence of target cells which have expressed surface epitopes that indicate intracellular infection by various viruses or other infectious agents, and also cells which have expressed surface epitopes that indicate the presence of non-infectious medical conditions. The analysis involves the examination of cells in the blood sample for the presence or absence of particular surface epitopes while the blood sample is disposed in a centrifuged blood sampling container. The epitopic analysis for the presence or absence of infected cells, or cells which indicate the presence of non-infectious medical conditions relies on the detection of known target expressed epitopes. The target epitopes on the target cell types are epitopes which are also known to be absent on normal circulating cells in the blood. Fluorophores or other labels with distinct wavelength emissions are coupled with specific binding agents such as lectins, antibodies, aptamers, or the like, which are directed against the target expressed epitopes. The epitopic analyses may be performed in or near the expanded buffy coat layer in the centrifuged blood sample. The epitopic analysis may be performed under magnification either visually and/or photometrically. The blood sampling container is sized to hold between about 1 and about 20 ml, preferably about 10 ml of blood, and contains an insert that occupies about 90-98% of the volume of the container bore in the area of the container where the target cells will, if present, be detected. The insert forces the target cells in question to reside in an annular space in the container which is adjacent to the circumference of the container bore. The entire analysis can be performed in a relatively short period of time which is typically a matter of minutes to single digit hours.

    Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
    9.
    发明授权
    Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood 失效
    全血中循环癌症和/或血液祖细胞的检测，鉴定，计数和确认方法

    公开(公告)号：US06197523B1

    公开(公告)日：2001-03-06

    申请号：US08976886

    申请日：1997-11-24

    申请人： David L. Rimm ,  Robert A. Levine ,  Stephen C. Wardlaw ,  Paul Fiedler

    发明人： David L. Rimm ,  Robert A. Levine ,  Stephen C. Wardlaw ,  Paul Fiedler

    IPC分类号： G01N33574

    CPC分类号： G01N15/042 ,  G01N33/56972 ,  G01N33/57484 ,  G01N2015/045 ,  Y10S436/813

    摘要： A method for analyzing blood enables one to isolate, detect, enumerate and confirm under magnification the presence or absence of target cancer cells and/or hematologic progenitor cells which are known to circulate in blood. The analysis is performed in a sample of centrifuged anticoagulated whole blood. The analysis involves both morphometric and epitopic examination of the blood sample while the blood sample is disposed in a centrifuged blood sampling tube. The epitopic analysis of the presence or absence of cancer cells relies on the detection of epitopes which are known to present only on cancer cells; and the epitopic analysis of the presence or absence of hematologic progenitor cells relies on the detection of epitopes which are known to present only on hematologic progenitor cells. The targeted epitopes on the target cell types are epitopes which are also known to be absent on normal circulating blood cells; and the target cancer cell epitopes are epitopes which are known to be absent on target hematologic progenitor cells. Fluorophors with distinct emissions are coupled with antibodies which are directed against the targeted epitopes. The morphometric analysis is performed by staining the cells in the blood sample with an intracellular stain such as acridine orange which highlights the intracellular cell structure. Both the morphometric and epitopic analyses are preferably performed at or near the platelet layer of the expanded buffy coat in the centrifuged blood sample. The morphometric analysis and/or the epitopic analysis may be performed under magnification both visually and/or photometrically.

    摘要翻译： 用于分析血液的方法使得能够在放大下分离，检测，枚举和确认已知在血液中循环的靶癌细胞和/或血液祖细胞的存在或不存在。 在离心的抗凝全血样品中进行分析。 该分析涉及血液样品的形态测定和表征检查，同时将血液样品置于离心取样管中。 癌细胞存在或不存在的代表性分析依赖于已知仅存在癌细胞的表位的检测; 并且血液祖细胞存在或不存在的表征分析依赖于已知仅存在血液祖细胞的表位的检测。 目标细胞类型上的靶向表位是已知在正常循环血细胞上不存在的表位; 并且目标癌细胞表位是已知在靶血液祖细胞上不存在的表位。 具有明显排放的荧光素与针对靶向表位的抗体相结合。 通过用细胞内染色剂如吖啶橙染色血液样品中的细胞进行形态测定分析，突出细胞内细胞结构。 形态测定和表征分析优选在离心血液样品中在扩张的血沉棕黄层的血小板层或其附近进行。 形态测定分析和/或表征分析可以在视觉上和/或光度下放大进行。

    Process for the preparation of 2-(4-chlorophenylethyl)-2-tert.-butyl-oxirane
    10.
    发明授权
    Process for the preparation of 2-(4-chlorophenylethyl)-2-tert.-butyl-oxirane 失效
    2-（4-氯苯乙基）-2-叔丁基 - 环氧乙烷的制备方法

    公开(公告)号：US4988829A

    公开(公告)日：1991-01-29

    申请号：US373770

    申请日：1989-06-30

    申请人： Paul Fiedler ,  Martin Littmann ,  Manfred Lenthe ,  Achim Noak ,  Gerd Siekmann

    发明人： Paul Fiedler ,  Martin Littmann ,  Manfred Lenthe ,  Achim Noak ,  Gerd Siekmann

    IPC分类号： C07D303/08

    CPC分类号： C07D303/08

    摘要： A process for making the known fungicide intermediate 2-(4-chlorophenyl ethyl)-2-tert.-butyloxirane of the formula ##STR1## comprising (a) mixing a solution of trimethylsulphonium bromide of the formula(CH.sub.3).sub.3 S.sup..sym. Br.sup..crclbar. (II) in a methanol/toluene mixture with preheated toluene and simultaneously distilling off a methanol/toluene mixture at a temperature between 65.degree. and 110.degree. C. until a suspension having a solids content between 10 and 70% by weight is formed, and(b) reacting the suspension of trimethylsulphonium bromide in toluene thus obtained with 1-(4-chlorophenyl)-4,4-dimethylpentan-3-one of the formula ##STR2## in the presence of solid potassium hydroxide, diethylene glycol and water at a temperature between 20.degree. and 120.degree. C., the amounts of the reaction components being such that per mole of 1-(4-chlorophenyl)-4,4-dimethylpentan-3-one of the formula (III) there are presentbetween 1 and 2 moles of trimethylsulphonium bromide of the formula (II),between 2 and 3 moles of solid potassium hydroxide and alsobetween 0.1 and 10% by weight of diethylene glycol and between 0.5 and 12% by weight of water, relative to 1-(4-chlorophenyl)-4,4-dimethylpentan-3-one of the formula (III).

    摘要翻译： 制备已知的杀真菌剂中间体式（I）的2-（4-氯苯基乙基）-2-叔丁基环氧乙烷的方法包括（a）将式（CH3）3S的三甲基锍溴化物 +）Br（ - ）（II）的甲醇/甲苯混合物中，同时在65-110℃的温度下蒸馏除去甲醇/甲苯混合物，直到固体含量为10至70％ ，并且（b）使由此获得的甲苯中的三甲基锍溴化物的悬浮液与式（III）的1-（4-氯苯基）-4,4-二甲基戊-3-酮在存在 固体氢氧化钾，二甘醇和水，温度在20℃至120℃之间，反应组分的量使得每摩尔1-（4-氯苯基）-4,4-二甲基戊-3-酮为 式（III）中存在1至2摩尔式（II）的三甲基锍溴化物，2至3小时 固体氢氧化钾和0.1至10重量％的二甘醇和0.5至12重量％的水相对于式（I）的1-（4-氯苯基）-4,4-二甲基戊-3-酮， （三）。